MA44492A - Compositions ophtalmiques comprenant une cyclodextrine en tant qu'agent actif unique - Google Patents

Compositions ophtalmiques comprenant une cyclodextrine en tant qu'agent actif unique

Info

Publication number
MA44492A
MA44492A MA044492A MA44492A MA44492A MA 44492 A MA44492 A MA 44492A MA 044492 A MA044492 A MA 044492A MA 44492 A MA44492 A MA 44492A MA 44492 A MA44492 A MA 44492A
Authority
MA
Morocco
Prior art keywords
active agent
compositions including
single active
ophthalmic compositions
including cyclodextrin
Prior art date
Application number
MA044492A
Other languages
English (en)
Inventor
Graham Edward Priestley
Original Assignee
Warneford Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warneford Healthcare Ltd filed Critical Warneford Healthcare Ltd
Publication of MA44492A publication Critical patent/MA44492A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA044492A 2016-11-18 2017-11-17 Compositions ophtalmiques comprenant une cyclodextrine en tant qu'agent actif unique MA44492A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1619525.7A GB2556082A (en) 2016-11-18 2016-11-18 Ophthalmic composition

Publications (1)

Publication Number Publication Date
MA44492A true MA44492A (fr) 2019-01-30

Family

ID=57993958

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044492A MA44492A (fr) 2016-11-18 2017-11-17 Compositions ophtalmiques comprenant une cyclodextrine en tant qu'agent actif unique

Country Status (9)

Country Link
US (1) US20190328772A1 (fr)
EP (1) EP3432862A1 (fr)
JP (1) JP2020510613A (fr)
CN (1) CN110087635A (fr)
AU (1) AU2017360116B2 (fr)
CA (1) CA3043660A1 (fr)
GB (1) GB2556082A (fr)
MA (1) MA44492A (fr)
WO (1) WO2018091859A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
EP2948149B1 (fr) 2013-01-23 2026-03-04 Aldeyra Therapeutics, Inc. Maladies liées à un aldéhyde toxique et traitement
EP4400106A1 (fr) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Composés deutérés et leurs utilisations
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
JP2022503994A (ja) * 2018-10-02 2022-01-12 アルデイラ セラピューティクス， インコーポレイテッド コンタクトレンズ溶液およびキット
KR20210142651A (ko) 2019-03-05 2021-11-25 코넬 유니버시티 망막 세포로부터 리포푸신 제거 활성을 갖는 물질의 조성물
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
WO2020223717A1 (fr) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Procédé de préparation d'un piégeur d'aldéhyde et d'intermédiaires
US10744153B1 (en) * 2019-07-01 2020-08-18 Cloudbreak Therapeutics Llc Compositions and methods for treating meibomian gland dysfunction
JP2023526016A (ja) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド 医薬製剤およびその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US8158609B1 (en) * 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
US10463687B2 (en) * 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
US20160151410A1 (en) * 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
US20180085392A1 (en) * 2015-04-17 2018-03-29 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging

Also Published As

Publication number Publication date
CA3043660A1 (fr) 2018-05-24
WO2018091859A1 (fr) 2018-05-24
GB2556082A (en) 2018-05-23
AU2017360116B2 (en) 2019-12-12
US20190328772A1 (en) 2019-10-31
GB201619525D0 (en) 2017-01-04
EP3432862A1 (fr) 2019-01-30
JP2020510613A (ja) 2020-04-09
AU2017360116A1 (en) 2019-05-30
CN110087635A (zh) 2019-08-02

Similar Documents

Publication Publication Date Title
MA44492A (fr) Compositions ophtalmiques comprenant une cyclodextrine en tant qu'agent actif unique
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
EP3442973A4 (fr) Nouveaux composés utilisés en tant qu'inhibiteurs de l'autotaxine et compositions pharmaceutiques les comprenant
EP3784665A4 (fr) Dérivés de pyridazine en tant qu'agents de dégradation de smarca2/4
EP3687543A4 (fr) Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv
MA48765A (fr) Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
EP3953331A4 (fr) Pyrazolesulfonamides en tant qu'agents antitumoraux
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
EP3324856A4 (fr) Compositions se fluidifiant par cisaillement en tant qu'agent embolique intravasculaire
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
EP3886879A4 (fr) Plaquettes en tant qu'agents de livraison
EP3694867C0 (fr) Dinucléotides cycliques utilisés en tant qu'agents anticancéreux
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
MA41341A (fr) Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
EP3334719A4 (fr) Benzimidazoles substitués, préparation et utilisation de ceux-ci en tant qu'agents pharmaceutiques
EP3487509A4 (fr) Désinfectants topiques émollients